REVLIMID® (lenalidomide) is indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1–risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials.

Lenalidomide, an analogue of thalidomide, has immunomodulatory, antiangiogenic, and antineoplastic properties in vitro1

Lenalidomide properties:



Immunomodulatory properties of lenalidomide include activation of T cells and natural killer (NK) cells, increased numbers of NKT cells and inhibition of pro-inflammatory cytokines (eg, TNF-α and IL-6) by monocytes.



Lenalidomide has demonstrated antiangiogenic properties.



It inhibits proliferation and induces apoptosis of certain hematopoietic tumor cells including del 5q myelodysplastic syndromes in vitro.

Learn about the presentation and diagnosis of MDS.

Explore Disease Overview